Context Therapeutics (CNTX) Competitors $0.69 -0.01 (-1.77%) Closing price 04:00 PM EasternExtended Trading$0.76 +0.07 (+9.40%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNTX vs. GLUE, TERN, PVLA, LFCR, TNGX, GOSS, CRVS, AQST, AVIR, and ATXSShould you be buying Context Therapeutics stock or one of its competitors? The main competitors of Context Therapeutics include Monte Rosa Therapeutics (GLUE), Terns Pharmaceuticals (TERN), Palvella Therapeutics (PVLA), Lifecore Biomedical (LFCR), Tango Therapeutics (TNGX), Gossamer Bio (GOSS), Corvus Pharmaceuticals (CRVS), Aquestive Therapeutics (AQST), Atea Pharmaceuticals (AVIR), and Astria Therapeutics (ATXS). These companies are all part of the "pharmaceutical products" industry. Context Therapeutics vs. Monte Rosa Therapeutics Terns Pharmaceuticals Palvella Therapeutics Lifecore Biomedical Tango Therapeutics Gossamer Bio Corvus Pharmaceuticals Aquestive Therapeutics Atea Pharmaceuticals Astria Therapeutics Monte Rosa Therapeutics (NASDAQ:GLUE) and Context Therapeutics (NASDAQ:CNTX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, community ranking, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends. Do analysts prefer GLUE or CNTX? Monte Rosa Therapeutics currently has a consensus price target of $15.50, indicating a potential upside of 290.43%. Context Therapeutics has a consensus price target of $6.00, indicating a potential upside of 765.93%. Given Context Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Context Therapeutics is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Context Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has more volatility and risk, GLUE or CNTX? Monte Rosa Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500. Comparatively, Context Therapeutics has a beta of 2.11, meaning that its share price is 111% more volatile than the S&P 500. Which has higher valuation and earnings, GLUE or CNTX? Context Therapeutics has lower revenue, but higher earnings than Monte Rosa Therapeutics. Context Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$159.49M1.53-$135.35M$0.0849.63Context TherapeuticsN/AN/A-$23.96M-$0.31-2.24 Does the MarketBeat Community prefer GLUE or CNTX? Context Therapeutics received 12 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 80.00% of users gave Context Therapeutics an outperform vote while only 47.06% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1647.06% Underperform Votes1852.94% Context TherapeuticsOutperform Votes2880.00% Underperform Votes720.00% Is GLUE or CNTX more profitable? Context Therapeutics' return on equity of -58.76% beat Monte Rosa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Context Therapeutics N/A -58.76%-55.80% Do institutionals & insiders have more ownership in GLUE or CNTX? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 2.8% of Context Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to GLUE or CNTX? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Context Therapeutics. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 2 mentions for Context Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 1.18 beat Context Therapeutics' score of 1.02 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Context Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryContext Therapeutics beats Monte Rosa Therapeutics on 10 of the 17 factors compared between the two stocks. Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTX vs. The Competition Export to ExcelMetricContext TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.16M$6.47B$5.33B$8.31BDividend YieldN/A2.64%5.20%4.10%P/E Ratio-0.768.4026.7219.60Price / SalesN/A258.84395.56117.96Price / CashN/A65.8538.3234.62Price / Book0.946.416.764.50Net Income-$23.96M$143.73M$3.23B$248.40M7 Day Performance-2.66%0.35%0.41%-1.00%1 Month Performance-26.58%2.05%9.12%10.72%1 Year Performance-64.47%-0.65%18.73%9.00% Context Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTXContext Therapeutics2.541 of 5 stars$0.69-1.8%$6.00+765.9%-63.8%$62.16MN/A-0.767Positive NewsGLUEMonte Rosa Therapeutics2.1255 of 5 stars$4.11+3.3%$15.50+277.1%-3.8%$252.81M$159.49M-2.2590Positive NewsAnalyst DowngradeTERNTerns Pharmaceuticals4.1009 of 5 stars$3.15+9.4%$15.63+396.0%-50.4%$251.53MN/A-2.6740News CoveragePositive NewsGap DownPVLAPalvella Therapeutics3.7812 of 5 stars$22.56+2.3%$46.29+105.2%N/A$249.13M$42.81M-1.86N/AAnalyst RevisionLFCRLifecore Biomedical1.2308 of 5 stars$6.71-2.6%$8.00+19.2%+14.4%$248.44M$130.31M-11.98690News CoverageAnalyst ForecastAnalyst RevisionGap UpTNGXTango Therapeutics1.8629 of 5 stars$2.29+52.7%$12.33+438.6%-74.8%$248.22M$40.99M-1.9490High Trading VolumeGOSSGossamer Bio3.701 of 5 stars$1.09+4.8%$7.75+611.0%+81.7%$247.67M$114.70M-3.41180Analyst RevisionCRVSCorvus Pharmaceuticals2.1969 of 5 stars$3.62+0.3%$16.33+351.2%+62.1%$246.77MN/A-3.8930Analyst ForecastAQSTAquestive Therapeutics1.2929 of 5 stars$2.45+2.9%$10.67+335.4%-27.3%$243.35M$54.23M-5.44160Gap DownAVIRAtea Pharmaceuticals2.4533 of 5 stars$2.81+2.6%$6.00+113.5%-25.4%$240.48MN/A-1.3670Analyst UpgradeATXSAstria Therapeutics1.9892 of 5 stars$4.26+7.6%$30.00+604.2%-55.2%$240.41MN/A-2.0430Gap Down Related Companies and Tools Related Companies GLUE Alternatives TERN Alternatives PVLA Alternatives LFCR Alternatives TNGX Alternatives GOSS Alternatives CRVS Alternatives AQST Alternatives AVIR Alternatives ATXS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNTX) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CNTX Stock Free CNTX Stock Alerts